Proactiveinvestors United Kingdom - Real Estate Holding & Development RSS feed Proactiveinvestors United Kingdom - Real Estate Holding & Development feed en Thu, 22 Feb 2018 19:08:38 +0000 Genera CMS Carillion investor tells MPs it considered suing contractor after first profit warning Mon, 19 Feb 2018 08:30:00 +0000 Carillion's facilities management contracts in line to be transferred to Canadian firm, BGIS Thu, 15 Feb 2018 09:44:00 +0000 MaxCyte defying the odds as it gears up for pivotal year Wed, 14 Feb 2018 11:52:00 +0000 MaxCyte appoints biotech pioneer as independent director Tue, 13 Feb 2018 08:04:00 +0000 J. Murphy & Son's buys Carillion's UK power framework business Wed, 07 Feb 2018 13:18:00 +0000 Carillion boss tells MPs he's 'truly sorry' for collapse of construction contractor Tue, 06 Feb 2018 11:16:00 +0000 Carillion collapse: True scale of fundamental flaws being revealed, says Unite union Tue, 30 Jan 2018 14:57:00 +0000 Carillion's troubles continue as accounting watchdog says to probe KPMG audits after profit warning Mon, 29 Jan 2018 07:41:00 +0000 Carillion directors to be questioned by MPs over contractor's collapse Wed, 24 Jan 2018 15:24:00 +0000 MaxCyte prepares for phase I study of potential cancer breakthrough; says trading in line with market expectations Mon, 22 Jan 2018 15:03:00 +0000 Carillion pleaded with government for short-term £150mln loan to avoid collapse Fri, 19 Jan 2018 13:13:00 +0000 Lloyds and Nationwide lend support to small firms hit by Carillion collapse Thu, 18 Jan 2018 15:50:00 +0000 Carillion debacle: Six lessons investors can draw from the construction contractor's collapse Tue, 16 Jan 2018 07:30:00 +0000 Carillion collapse puts contracts at risk but presents opportunities for sector peers Mon, 15 Jan 2018 12:04:00 +0000 Carillion collapse confirmed as firm takes steps to enter compulsory liquidation Mon, 15 Jan 2018 07:50:00 +0000 Carillion plunges on reports lenders have rejected its debt restructuring plan Fri, 12 Jan 2018 16:00:00 +0000 Carillion shares drop as investors await any news out of Wednesday’s crucial lenders Thu, 11 Jan 2018 13:21:00 +0000 Carillion issues brief, dismissive response to share price leap on chatter it's close to a rescue deal Tue, 09 Jan 2018 08:30:00 +0000 Carillion to present revised business plan as it fights for survival Mon, 08 Jan 2018 07:29:00 +0000 Carillion: Where it all went wrong for the mega-cap turned micro-cap UK contractor Wed, 03 Jan 2018 12:54:00 +0000 FCA launches investigation into Carillion for company announcements Wed, 03 Jan 2018 08:20:00 +0000 Year past and year ahead: Carillion, Lloyds, RBS and BT Group in focus Sun, 31 Dec 2017 12:00:00 +0000 Carillion says still in discussion with stakeholders regarding debt reduction options, expects to take action in the first quarter 2018 Fri, 22 Dec 2017 08:03:00 +0000 Carillion's new boss to start earlier to lead turnaround of troubled contractor Wed, 20 Dec 2017 10:00:00 +0000 Carillion inks definitive sale agreement for disposal of bulk of its UK healthcare facilities business Wed, 13 Dec 2017 11:10:00 +0000 Carillion shares up as stock overhang cleared after biggest shareholder, Kiltearn halves stake Mon, 11 Dec 2017 12:43:00 +0000 Circle Property assets climb as refurbishments and locations prove worth Thu, 07 Dec 2017 10:41:00 +0000 Carillion selected in school building framework despite fresh profit warning Mon, 20 Nov 2017 15:15:00 +0000 Analysts think Carillion's most likely route to survival is through a debt for equity swap Fri, 17 Nov 2017 14:53:00 +0000 Government fuels speculation of intervention into Carillion as it responds to profit warning Fri, 17 Nov 2017 13:49:00 +0000 MaxCyte Inc gearing up for phase I study of potential cancer breakthrough Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer disease.

Doerfler adds they're in active discussions with the US Food & Drug Administration to begin the study later this year of MCY-M11, which is based on its CARMA technology.

Tue, 23 Jan 2018 11:53:00 +0000
Investors left in the lurch as Carillion goes into liquidation ETX Capital's senior market analyst Neil Wilson gives his view on the collapse of Carillion PLC (LON:CLLN).

The construction company confirmed its collapse today after the failure of talks with key financial and other stakeholders, including the UK government over the course of the weekend and has taken steps to enter into compulsory liquidation with immediate effect.

Mon, 15 Jan 2018 12:07:00 +0000
All good news for Circle Property as demand for provincial office space remains strong John Arnold, chief executive of Circle Property PLC (LON:CRC), tells Proactive they've recorded another six months of strong rental growth and rising asset values.

On a per share basis, assets rose by 15.3% to 211p, making a 40% uplift since the company joined AIM in February 2016.

Rental income rose by 26% to £2.9mln with the interim dividend 8% higher at 2.6p.

Over the half, Circle negotiated rent increases worth £379,000 or 7.2%.

Tue, 12 Dec 2017 08:33:00 +0000
Carillion fighting for survival after third profit warning Michael Van Dulken from Accendo Markets speaks to Proactive after Carillion PLC (LON:CLLN) warned that profits for the year would be “materially lower than market expectations” and that its debt pile will increase.

It marked the third profit warning for the year and comes on the back on falling revenues, rising costs and project delays in the Middle East.

Fri, 17 Nov 2017 15:09:00 +0000
UK Commercial Property Trust truly diversified across £1.4bln worth of assets Will Fulton, manager of the UK Commercial Property Trust (LON:UKCM), tells Proactive they're a diversified investment trust focused on retail, industrial as well as office assets.

''The tilt of the portfolio at the moment is towards industrial which I really like, we've added to that, we've probably sold away some retail and some central London'',

''We're diversified across £1.4 bln worth of assets - spread geographically across the country and also spread by tenant - we don't like to put too much money into one tenant''.

Thu, 12 Oct 2017 09:08:00 +0100
Circle Property encouraging occupancy through competitive rents John Arnold, chief executive of Circle Property plc (LON:CRC), tells Proactive they specialise in out-of-town offices and are particularly strong in the provinces.

''We've been investing in Bristol,  Milton Keynes, Northampton, Birmingham ... all the locations where there's good demand from tenants, where the location justifies the risk of doing refurbishment''.

Fri, 15 Sep 2017 15:19:00 +0100
Sirius Real Estate enjoying good growth as they eye $1.2bln property portfolio Based in Berlin, Andrew Coombs, chief executive of Sirius Real Estate Limited (LON:SRE) tells Proactive their focus is on business parks in the country.

''We have 47 business parks across Germany consisting of nearly 500 buildings''.

As to why they're keen on doing business in Germany, Coombs says: ''The price that you can buy property for versus the cost of replacing it is widely different and what that means is you can buy German business parks at  quite a low cost and you can develop a good business with a good margin without the worry of people simply just moving in to a brand new property''.

''Secure, predictable and reliable - we're all about risk-adjusted returns throughout the cycle'', Coombs adds.

Wed, 26 Jul 2017 08:41:00 +0100
Carillion 'dragged through a hedge fund backwards' - Proactive's John Harrington Proactive Investors correspondent John Harrington reports on the recent hammering of Carillion PLC (LON:CLLN).

JP Morgan has downgraded the construction services firm to ‘neutral’ from ‘overweight’ on the back of Monday’s trading update in which its chief executive resigned after warning investors that full-year revenues would be lower than expected.

Thu, 13 Jul 2017 14:28:00 +0100
MaxCyte's Doug Doerfler 'confident of providing long-term treatment' for CGD patients Doug Doerfler, president and chief executive of MaxCyte, Inc. (LON:MXCT) tells Proactive they're to continue their collaboration with one of the world’s leading infectious disease institutes after signing a cooperative research and development agreement with the US National Institute of Allergy and Infectious Diseases (NIAD).

The two will work together to explore the development of new therapies for X-linked chronic granulomatous disease (CGD) using MaxCyte’s Flow Electroporation gene-correction platform.

Tue, 06 Jun 2017 15:25:00 +0100
Doug Doerfler on the 'incredibly exciting' opportunities ahead for Maxcyte Doug Doerfler, chief executive of MaxCyte PLC (LON:MXCT) updates Proactive Investors on developments with their gene editing technology and pre-clinical programmes.


Fri, 26 May 2017 12:19:00 +0100
'We're still a bit under the radar', says Palace Capital's Neil Sinclair Neil Sinclair, chief executive of Palace Capital Plc (LON:PCA) tells Proactive's Andrew Scott: ''We feel the regions, particularly Manchester, Leeds and Liverpool and ultimately Newcastle … are going to grow and will continue to grow''.

Sinclair says their portfolio at the moment is worth around £180mln with debt of around £70mln giving them a net asset value of close to £110mln.

''We're conservative, we don't buy very often but when we do we really go for it'', Sinclair adds.

''We think we're unique because we only buy properties in the right towns and in the right places in the right towns''.

Mon, 10 Apr 2017 18:00:00 +0100
MaxCyte boss Doerfler excited by gene-editing licence deal Doug Doerfler, chief executive of MaxCyte, runs through the firm's first commercial licence deal in the gene-editing space.
Under the deal, CRISPR Therapeutics (NASDAQ:CRSP) and its joint-venture with Bayer AG, a company called Casebia Therapeutics, have picked up a licence to use MaxCyte’s technology.
CRISPR Therapeutics and Casebia will get non-exclusive commercial-use rights to MaxCyte's cell engineering platform.
"It's a very exciting time for the company and it's really a pleasure to be working with this advanced group that’s working in the area of inherited blood disorders," said Doerfler.

Tue, 14 Mar 2017 16:21:00 +0000
MaxCyte's latest deal 'a perfect relationship' says CEO Doug Doerfler MaxCyte Inc (LON:MXCT) chief executive Doug Doerfler tells Proactive: ''This is the second relationship we have inked using our CARMA platform''.

CARMA retrains the cells found in blood to attack cancer.

The AIM-listed life sciences group is teaming up with Washington University in St Louis and will use CARMA to develop immunotherapy drug candidates.

Wed, 21 Dec 2016 14:25:00 +0000
MaxCyte driving CARMA forwards The first trading update of cell engineering specialist MaxCyte Inc (LON:MXCT) since listing on AIM was a good one, leaving founder and chief executive Doug Doerfler very confident over prospects for the current year.
Doerfler said the company had just had a very solid year in China in the financial year just ended, and the company plans to up its marketing efforts in the current year to build on this success in the People’s Republic and in other parts of the world.
The MaxCyte boss also expanded on the other main string to the company’s bow, which is the CARMA platform.
“It creates immune-based cancer treatments directly from patients’ cells,” Doerfler explained.
The platform is directing this new type of therapy towards solid tumours, in conjunction with the world-famous John Hopkins Hospital in Baltimore.
“It is a huge opportunity for the company, and a very significant unmet medical need of patients,” Doerfler told Proactive Investors.

Wed, 13 Jul 2016 14:56:00 +0100
MaxCyte chief says potential of breakthrough technology CARMA should not be underestimated Newly-listed MaxCyte (LON:MXCT) is a drug discovery company that also licences and sells its cell technology. 
Chief executive Doug Doerfler talks to Proactive’s Charlotte Kan about the company’s hybrid model, which means it is one of the few biotechs actually generating substantial revenues. “It is an unusual, but good position to be,” he says.
Doerfler also gives us an insight into its potential blockbuster, CARMA, which is being developed to re-programme the body’s immune system to kill cancer.
“I can’t overestimate how important this for medicine and also for the company,” Doerfler adds.

Wed, 11 May 2016 13:36:00 +0100
K&C launch first residential REIT in London K&C Reit(LON:KCR), the central London focussed real estate group, has launched the first residential real estate investment trust onto the AIM market. The CEO, Tim James, tells Proactive Investors that they want to be a five hundred million pound business and already have £40 million of deals in the pipeline.

K&C  has agreed to acquire Silcott Properties which owns several prime residential properties in Chelsea. The UK government recently extended the tax breaks for REITs to residential property and Tim James believes that a lot of developers and SPVs are currently unaware of the benefits of this new investment vehicle.

Fri, 03 Jul 2015 09:02:00 +0100